Logo

Eisai's Fycompa (perampanel) Receives EC's Approval for Expanded Indication in Pediatric Patients with POS and PGTCS

Share this

Eisai's Fycompa (perampanel) Receives EC's Approval for Expanded Indication in Pediatric Patients with POS and PGTCS

Shots:

  • The approval extends the use of Fycompa as adjunctive therapy for POS (with/out secondary generalization) by expanding the approved age range from 12yrs.+ to 4yrs.+ and for PGTCS from 12yrs.+ to 7yrs.+
  • The approval is based on P-III 311 study assessing Fycompa (oral suspension) as adjunctive therapy in 180 pediatric patients (aged 4-12 yrs.) with POS or PGTCS
  • The 232 study involves assessing the PK- efficacy- and long-term safety of Fycompa taken at the same time as other AEDs therapy in 63 pediatric patients with epilepsy in patients aged 2 to >12yrs. Fycompa is an AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures

­  Ref: Eisai | Image: Pinterest

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions